Figure 3. Comparison between the effects of ranibizumab and control antibody on HTFs (continuous 48 h) in serum-free condition. Ranibizumab 0.5 mg/ml induced significant human Tenon’s fibroblast (HTF) death at 48 h in serum-free conditions compared to the control isotype (n=3).